NCT03302208 is a Phase 3 clinical trial of Pregabalin in Hysterectomy, sponsored by Nesrine El-Refai.

Who is sponsoring NCT03302208?

NCT03302208 is sponsored by Nesrine El-Refai.

What drugs are being tested in NCT03302208?

Interventions in NCT03302208: Pregabalin, Placebo.

What condition does NCT03302208 study?

NCT03302208 studies Hysterectomy.

Is NCT03302208 still recruiting?

NCT03302208 is currently completed. Last updated 9 January 2018.

Last reviewed 2018-01-09 · How we verify

NCT03302208

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Preoperative Oral Pregabalin Effect on Inhalational Anesthetic Requirements ln Hysterectomy Under General Anesthesia

Completed Phase 3 Last updated 9 January 2018

What this trial tests

Phase 3 trial testing Pregabalin in Hysterectomy in 50 participants. Completed in 20 September 2017.

Timeline

29 June 2017

Primary endpoint
1 September 2017

20 September 2017

Quick facts

Lead sponsor	Nesrine El-Refai
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	health services research
Enrollment	50
Start date	29 June 2017
Primary completion	1 September 2017
Estimated completion	20 September 2017
Sites	1 location across Egypt

Drugs / interventions tested

Pregabalin (Pregabalin) — full drug profile →
Placebo

Conditions studied

Hysterectomy — all drugs for Hysterectomy →

Sponsor

Nesrine El-Refai

Who can join

Adults 18 to 60, female only, with Hysterectomy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study the investigators hypothesized that preoperative pregabalin tablet (150 mg orally ) may be effective in reducing intraoperative isoflurane requirements needed to maintain intraoperative hemodynamics within ± 20% of baseline measurement and/or attenuates hemodynamic response to endotracheal intubation in female patients ASA I or II , aged 18-60 years, schedule for elective abdominal hysterectomy surgery under general anesthesia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Pregabalin

Trials testing the same drug.

NCT07288528 — A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Ref · Phase 4 · not yet recruiting
NCT07421427 — Adding Amantadine or Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain Syndrome · NA · recruiting
NCT07275762 — Y-4 to Treat the Postherpetic Neuralgia · Phase 2 · recruiting
NCT07208357 — The Efficacy and Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibromyalgia · NA · recruiting
NCT07196657 — The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia · NA · recruiting

Other recruiting trials for Hysterectomy

Currently open trials in the same condition.

NCT07324967 — A Standardized Counseling Approach to Preoperative Education in Transmasculine Individuals Receiving Gender-affirming Su · NA · recruiting
NCT07120529 — Minimally Invasive Surgery Versus Open Radical Hysterectomy in Presumably Early Stage Cervical Cancer: a Retrospective M · recruiting
NCT06996561 — Exploring the Impact of Genetic Variations on The Clinical Efficacy of Nalbuphine in Postoperative Pain Management · Phase 2, PHASE3 · recruiting
NCT06969326 — Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy · Phase 3 · recruiting
NCT06719180 — Vaginal Cuff Anesthesia and Post-Operative Pain Medication Use · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03302208 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nesrine El-Refai
Last refreshed: 9 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03302208.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing